Vaughan Nelson Investment Management, L.P. Vertex Pharmaceuticals Inc Transaction History

Vaughan Nelson Investment Management, L.P.

$10.8 Billion
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$314.42 - $351.91 $2.24 Million - $2.51 Million	7,122 Added 1.5%	482,572 $170 Million
Q1 2023 May 05, 2023	SELL	$283.23 - $323.1 $761,322 - $868,492	-2,688 Reduced 0.56%	475,450 $150 Million
Q4 2022 Jan 30, 2023	SELL	$285.76 - $321.48 $7.46 Million - $8.4 Million	-26,123 Reduced 5.18%	478,138 $138 Million
Q3 2022 Nov 04, 2022	SELL	$273.83 - $305.53 $97.8 Million - $109 Million	-357,332 Reduced 41.47%	504,261 $146 Million
Q2 2022 Jul 22, 2022	SELL	$234.96 - $292.55 $1.65 Million - $2.05 Million	-7,024 Reduced 0.81%	861,593 $243 Million
Q1 2022 May 04, 2022	SELL	$221.42 - $260.97 $12.2 Million - $14.4 Million	-55,130 Reduced 5.97%	868,617 $227 Million
Q4 2021 Jan 13, 2022	BUY	$177.01 - $223.45 $164 Million - $206 Million	923,747 New	923,747 $203 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

Capital World Investors Los Angeles, CA

26.7M
Shares

$12.7 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$10.9 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.1 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.56 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.05 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vaughan Nelson Investment Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Vaughan Nelson Investment Management, L.P. with notifications on news.

Account